Q-omics provides the consensus-scored GRK4 profile across patient tissues and cancer cell-line models. GRK4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GRK4 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, GRK4 RNA expression shows 19,511 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, HNSC, and UVM as cancer lineages where GRK4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRK4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRK4 survival associations across molecular data types. GRK4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRK4 RNA expression–survival associations across cancer types. High GRK4 expression shows unfavorable associations in KICH, MESO, UVM, ACC, KIRP and UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for GRK4 RNA expression.
This table summarizes GRK4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for GRK4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRK4 shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, KIRP and PRAD. The HNSC box plot shows higher GRK4 RNA expression in tumor versus normal tissue (log2 FC = +0.954, t-test p < 0.001).
This table shows molecular features associated with GRK4 in patient tissues and cancer cell lines. In patient samples, GRK4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRK4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
